Wells Fargo & Company Assembly Biosciences, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.65 - $1.25 $79 - $152	122 Added 31.77%	506 $0
Q3 2023 Nov 13, 2023	BUY	$0.87 - $1.13 $7 - $10	9 Added 2.4%	384 $0
Q2 2023 Aug 15, 2023	BUY	$0.81 - $1.15 $30 - $43	38 Added 11.28%	375 $0
Q1 2023 May 12, 2023	BUY	$0.8 - $1.74 $4 - $8	5 Added 1.51%	337 $0
Q4 2022 Feb 13, 2023	BUY	$1.09 - $20.4 $10 - $204	10 Added 3.11%	332 $0
Q3 2022 Nov 14, 2022	BUY	$1.7 - $20.52 $59 - $718	35 Added 12.2%	322 $1,000
Q2 2022 Aug 12, 2022	BUY	$1.35 - $2.29 $33 - $57	25 Added 9.54%	287 $1,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.45 $1 - $2	1 Added 0.38%	262 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $287 - $467	135 Added 107.14%	261 $1,000
Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $387,240 - $480,967	-123,325 Reduced 99.9%	126 $0
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $439,120 - $526,944	115,558 Added 1464.06%	123,451 $479,000
Q1 2021 May 13, 2021	SELL	$4.33 - $6.63 $303,372 - $464,517	-70,063 Reduced 89.88%	7,893 $37,000
Q4 2020 Feb 09, 2021	BUY	$4.87 - $17.29 $82,439 - $292,685	16,928 Added 27.74%	77,956 $472,000
Q3 2020 Nov 05, 2020	SELL	$15.08 - $27.04 $121,906 - $218,591	-8,084 Reduced 11.7%	61,028 $1 Million
Q2 2020 Aug 13, 2020	BUY	$14.57 - $23.96 $436,925 - $718,512	29,988 Added 76.65%	69,112 $1.61 Million
Q1 2020 May 14, 2020	BUY	$10.27 - $21.23 $401,803 - $830,602	39,124 New	39,124 $580,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.